• BCECF-AM: Precision Intracellular pH Sensing Beyond Protocol

  2026-05-28

  Explore the scientific principles and advanced applications of BCECF-AM, a leading intracellular pH indicator. This in-depth analysis goes beyond standard protocols to reveal how bis(acetoxymethyl) 3,3'-(3',6'-bis(acetoxymethoxy)-5-((acetoxymethoxy)carbonyl)-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-2',7'-diyl)dipropanoate empowers transformative research in cell biology.

• Peripheral RIPK1 and IL-8 as ALS Biomarkers: Primidone Repur

  2026-05-27

  This study establishes elevated peripheral RIPK1 and IL-8 as robust biomarkers for amyotrophic lateral sclerosis (ALS) and demonstrates that Primidone, long used as an antiepileptic, can significantly reduce these biomarkers in both mouse models and human patients. The findings offer new perspectives on biomarker-driven patient stratification and the repurposing of Primidone for ALS intervention.

• Saracatinib (AZD0530): Precision Src/Abl Inhibition in Cance

  2026-05-27

  Saracatinib (AZD0530) delivers robust, selective Src and Abl kinase inhibition, empowering researchers to dissect oncogenic signaling and cell migration with unparalleled reproducibility. Discover protocol refinements, troubleshooting tips, and novel translational insights—directly informed by cutting-edge synaptic signaling research—for advanced cancer biology and neuroscience applications.

• SIRT1/2 Inhibitor IV (Cambinol): Next-Gen Insights for Metab

  2026-05-26

  Discover how SIRT1/2 Inhibitor IV (cambinol) enables advanced exploration of metabolic and CNS pathways, including SIRT1-regulated lactylation and tumor suppression. This in-depth analysis reveals new experimental strategies and practical assay guidance for researchers.

• Deferasirox in Cancer Research: Iron Chelation, Ferroptosis,

  2026-05-26

  Explore how Deferasirox, an oral iron chelator, is transforming translational oncology by targeting iron metabolism and overcoming ferroptosis resistance in tumors. This article bridges mechanistic insights with actionable strategies for researchers, referencing new findings on the METTL16-SENP3-LTF axis and highlighting APExBIO's role in advancing experimental workflows.

• FK866 (APO866): NAMPT Inhibition for Cancer Metabolism Resea

  2026-05-25

  FK866 (APO866) is a potent, non-competitive NAMPT inhibitor used in cancer and vascular aging research. It selectively depletes intracellular NAD, triggering caspase-independent cell death in malignant cells while sparing normal progenitors. Robust in vitro and in vivo data support its application in acute myeloid leukemia (AML) research and mechanistic studies of NAD metabolism.

• Distinct Volatile Mechanisms of Chuanxiong Cortex and Pith i

  2026-05-25

  This study uses advanced SPME-GC×GC-MS and network pharmacology to reveal how the cortex and pith of Ligusticum chuanxiong differ in volatile composition and mechanistic pathways for coronary heart disease (CHD) intervention. The findings clarify the specific bioactive molecules, including 1-Phenyl-1-pentanol (Fenipentol), and their target pathways, informing new directions for gastrointestinal and cardiovascular research.

• Elobixibat Hydrate: Protocols for IBAT Inhibition in GI Rese

  2026-05-24

  Elobixibat hydrate, a selective ileal bile acid transporter inhibitor, enables translational workflows for chronic idiopathic constipation, colonoscopy preparation, and metabolic modulation in T2DM. This guide distills experimental design, protocol optimizations, and troubleshooting strategies to maximize reproducibility and clinical relevance.

• DDX21/NAT10-Mediated ac4C RNA Modification Drives CRC Metast

  2026-05-23

  This study identifies a novel regulatory axis in colorectal cancer (CRC) wherein DDX21 competitively binds SIRT7, enhancing NAT10-mediated ac4C RNA modification to stabilize pro-metastatic mRNAs. The findings offer mechanistic insight into CRC angiogenesis and metastasis, informing potential molecular targets for intervention.

• ECL Chemiluminescent Substrate Detection Kit: Pushing Sensit

  2026-05-22

  Explore how the ECL Chemiluminescent Substrate Detection Kit advances horseradish peroxidase (HRP) chemiluminescence for ultra-sensitive immunoblotting. This article reveals new scientific insights and practical strategies for reliable detection of low-abundance proteins, offering a distinct perspective beyond existing content.

• HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody: Practic

  2026-05-22

  The HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody addresses the need for sensitive, reproducible detection of rabbit primary antibodies in fluorescence-based assays. It is best suited for immunofluorescence, flow cytometry, and fluorescence microscopy workflows where high specificity and minimal cross-reactivity are critical. This reagent should not be used outside established protocols for rabbit IgG detection, nor in non-fluorescent or non-immunological contexts.

• GluN2B R519Q Variant Drives NMDAR Degradation via Autophagy

  2026-05-21

  Benske et al. uncover how the disease-associated R519Q variant in the GluN2B subunit of NMDA receptors is selectively degraded through the autophagy-lysosomal pathway. This mechanistic insight advances understanding of NMDAR proteostasis and suggests new strategies for targeting receptor variants in neurodevelopmental disorders.

• Clasto-Lactacystin β-lactone: Proteasome Inhibitor in Cellul

  2026-05-21

  Clasto-Lactacystin β-lactone delivers unparalleled specificity and potency for dissecting the ubiquitin-proteasome pathway, powering advanced studies in inflammation, cancer, and viral immune evasion. Its irreversible, cell-permeable action enables robust, reproducible results in proteasome inhibition assays, even in complex disease models.

• Optimized Differentiation of Functional Platelets from hiPSC

  2026-05-20

  This study presents an optimized, cost-effective protocol for generating functional platelets from human induced pluripotent stem cells (hiPSCs), addressing scalability and efficiency barriers in platelet production. By integrating enhanced embryoid body seeding, serum-free media with human platelet lysate, and strategic small molecule supplementation, the protocol improves yield and reduces costs, with direct implications for cell therapy and gene editing.

• AG-490 (Tyrphostin B42): Applied Workflows for JAK2/STAT6 In

  2026-05-20

  AG-490 (Tyrphostin B42) empowers researchers to dissect oncogenic and immunomodulatory signaling by selectively inhibiting JAK2 and EGFR. Recent evidence connecting exosomal SNORD52 to JAK2/STAT6-driven macrophage polarization in hepatocellular carcinoma spotlights AG-490's pivotal role in tumor microenvironment studies.

406 records 7/28 page Previous Next First page 上5页 678910 下5页 Last page